Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy

Science Advances(2023)10.1126/sciadv.ade6675Source: DataRank Database

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy is a research paper published in Science Advances (2023). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 1.61)OA: goldTopics (53)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (31)

Raquel Crespo ORCID,Cynthia Lungu ORCID,Shringar Rao ORCID,Letao Li ORCID,Ronald J. Overmars ORCID

Live enrichment

PubMed:36921041 PMC:PMC10017042 OpenAlex:https://openalex.org/W4324324998

European Commission

Grant: 681032

European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates

FWCI

1.61

Citation Percentile

0.8%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.science.org/doi/pdf/10.1126/sciadv.ade6675?download=true

GOLDhttps://www.science.org/doi/pdf/10.1126/sciadv.ade6675?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/sciadv.ade6675?download=true

publisherhttps://www.science.org/doi/pdf/10.1126/sciadv.ade6675

journalhttps://doi.org/10.1126/sciadv.ade6675

Fields of Study

HIV Research and TreatmentHIV/AIDS drug development and treatmentHIV-related health complications and treatmentsMedicine0303 health sciences03 medical and health sciencesHumansCD4-Positive T-LymphocytesHIV InfectionsHIV-1PyrimethamineRNAValproic AcidVirus ActivationVirus Latency

MeSH Terms

HumansPyrimethamineRNAValproic AcidVirus ActivationCD4-Positive T-LymphocytesHIV-1HIV InfectionsVirus Latency

Keywords

PyrimethamineValproic AcidPharmacologyHuman immunodeficiency virus (HIV)MedicineAntiretroviral therapyIn vivoLentivirusDrugViral loadVirologyImmunologyEpilepsyBiologyMalariaPlasmodium falciparumPsychiatryViral diseaseCD4-Positive T-LymphocytesRadboud University Medical CenterHIV InfectionsVirus LatencySDG 3 - Good Health and Well-beingHIV-1HumansRNARadboudumc 4: lnfectious Diseases and Global Health Clinical PharmacyVirus ActivationBiomedicine and Life Sciences

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being